Table 2 One-year outcomes

Patients, n

39

60

Baseline VA logMAR, mean (SD)

1.13 (0.61)

0.75 (0.42)

0.001

Final VA logMAR, mean (SD)*

0.92 (0.75)

0.4 (0.4)

< 0.001

Change VA logMAR*,

mean (95% CI)

−0.2

(− 0.43, 0.02)

−0.35

(− 0.46, − 0.23)

0.25

VA ≤ 0.3 logMAR, % (baseline/final*)

10 / 36

20 / 63

0.01

VA ≥ 1 logMAR, % (baseline/final*)

59 /47

37 /12

< 0.001

Improvement ≥3 lines*, %

32

60

0.37

Worsening ≥3 lines*, %

8

7

0.31

Baseline IOP mmHg, mean (SD)

19 (11)

16 (3)

0.07

Final IOP mmHg, mean (SD)*

17 (2)

15 (5)

0.05

Change IOP mmHg*,

mean (95% CI)

−3

(−6, 0)

−2

(−4, −1)

0.64

Baseline CST μm, mean (SD)

519 (213)

423 (151)

0.02

Final CST μm, mean (SD)*

343 (160)

281 (133)

0.09

Change CST μm*,

mean (95% CI)

−184

(−276, −91)

− 114

(− 189, −40)

0.24

Injections ^α, median (Q1, Q3)

2 (1, 3)

2 (1, 3)

1

Additional Macular Laser, n

0

2

0.52

Additional Triamcinolone, n

2

2

0.65

Additional PRP/Sectoral Laser, n

16

15

0.17